Phase II clinical trials of WT1 vaccine for post hematopoietic stem cell transplant patients
Phase 1
- Conditions
- Acute leuekmia
- Registration Number
- JPRN-UMIN000013262
- Lead Sponsor
- Osaka university graduate school of medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1)active infectious diseases 2)Severe Complications, including Heart failure, Renal faiure, Hapatic failure, ileus, uncontrolable DM, and so on 3)Other severe problems unsuitable for this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie WT1 vaccine efficacy in post-hematopoietic stem cell transplant acute leukemia patients?
How does the WT1 vaccine compare to standard-of-care therapies for relapse prevention in AML and ALL post-transplant?
Which biomarkers correlate with clinical response to WT1 peptide vaccination in hematopoietic stem cell transplant recipients?
What are the immune-related adverse events associated with WT1-targeted immunotherapy in post-transplant leukemia patients?
Are there synergistic combination strategies involving WT1 vaccines and checkpoint inhibitors for hematologic malignancies post-HSCT?